- Home
- SAND vs IMCR Comparison
SAND vs IMCR Comparison
Compare SAND & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- IMCR
- Stock Information
- Founded
- SAND 2007
- IMCR 2008
- Country
- SAND Canada
- IMCR United Kingdom
- Employees
- SAND N/A
- IMCR N/A
- Industry
- SAND
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAND
- IMCR Health Care
- Exchange
- SAND NYSE
- IMCR Nasdaq
- Market Cap
- SAND 1.8B
- IMCR 1.7B
- IPO Year
- SAND N/A
- IMCR 2021
- Fundamental
- Price
- SAND $5.82
- IMCR $32.12
- Analyst Decision
- SAND Buy
- IMCR Buy
- Analyst Count
- SAND 3
- IMCR 13
- Target Price
- SAND $9.33
- IMCR $68.73
- AVG Volume (30 Days)
- SAND 3.6M
- IMCR 237.7K
- Earning Date
- SAND 11-07-2024
- IMCR 11-06-2024
- Dividend Yield
- SAND 0.97%
- IMCR N/A
- EPS Growth
- SAND 142.46
- IMCR N/A
- EPS
- SAND 0.12
- IMCR N/A
- Revenue
- SAND $173,381,000.00
- IMCR $296,312,000.00
- Revenue This Year
- SAND $1.65
- IMCR $28.88
- Revenue Next Year
- SAND $15.64
- IMCR $12.61
- P/E Ratio
- SAND $48.76
- IMCR N/A
- Revenue Growth
- SAND N/A
- IMCR 25.09
- 52 Week Low
- SAND $3.96
- IMCR $29.72
- 52 Week High
- SAND $6.50
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- SAND 49.85
- IMCR 46.91
- Support Level
- SAND $5.34
- IMCR $30.52
- Resistance Level
- SAND $6.38
- IMCR $33.61
- Average True Range (ATR)
- SAND 0.19
- IMCR 1.68
- MACD
- SAND -0.01
- IMCR -0.14
- Stochastic Oscillator
- SAND 45.67
- IMCR 39.00
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.